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Abstract
The effectiveness of disease-modifying drugs in the treatment of multiple sclerosis is asso-
ciated with adherence. RebiSmart1 electronic device provides useful information about
adherence to the treatment with subcutaneous (sc) interferon (IFN) β-1a (Rebif1). The aim
of the study was to determine long-term adherence to this treatment in patients with relaps-
ing-remitting multiple sclerosis (RRMS). This retrospective multicentre observational study
analysed 258 patients with RRMS who were receiving sc IFN β-1a (Rebif1) treatment by
using RebiSmart1 until replacement (36 months maximum lifetime) or treatment discontinu-
ation. Adherence was calculated with data (injection dosage, time, and date) automatically
recorded by RebiSmart1. Patients in the study had a mean age of 41 years with a female
proportion of 68%. Mean EDSS score at start of treatment was 1.8 (95% CI, 1.6–1.9). Over-
all adherence was 92.6% (95% CI, 90.6–94.5%). A total of 30.2% of patients achieved an
adherence rate of 100%, 80.6% at least 90%, and only 13.2% of patients showed a subopti-
mal adherence (<80%). A total of 59.9% of subjects were relapse-free after treatment initia-
tion. Among 106 subjects (41.1%) who experienced, on average, 1.4 relapses, the majority
were mild (40.6%) or moderate (47.2%). Having experienced relapses from the beginning
of the treatment was the only variable significantly related to achieving an adherence of at
least 80% (OR = 3.06, 1.28–7.31). Results of this study indicate that sc IFN β-1a administra-
tion facilitated by RebiSmart1 could lead to high rates of adherence to a prescribed dose
regimen over 36 months.
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Introduction
Multiple sclerosis (MS) is an autoimmune and chronic disease characterized by inflammation,
demyelination and axonal degeneration occurring in the central nervous system [1,2]. Most
patients are between 25–35 years of age when diagnosed, and they are mainly women. The
prevalence in Spain ranges around 70–80 to 125 cases per 100,000 inhabitants, depending on
the geographical area, and the used methodology [3,4]. Approximately 70–80% of patients
develops the relapsing-remitting form (RRMS), defined by recurrent episodes of neurological
dysfunction, and followed by partial or full recovery [5]. Although to date there is no cure for
MS, first-line treatment with disease-modifying drugs (DMDs), such as interferon (IFN) β-1a,
IFN β-1b, and glatiramer acetate, have demonstrated to reduce the incidence and severity of
relapses and disability progression [6–9]. Apart from this partial effect, the efficacy of treat-
ments is being compromised by the lack of persistence and adherence to the prescribed dura-
tion, interval and dosing [10,11]. Patients with poor adherence, or who discontinued the
treatment, have reported higher incidence of relapses and experienced worse quality of life
than adherent patients [12–15]. Indeed, adherence to injectable DMD therapies is generally
suboptimal [11].
The Global Adherence Project (GAP), a multicentre, multinational phase IV study that
involved 2,566 patients with RRMS, revealed a non-adherence rate of 25% to prescribed regi-
mens (intramuscular IFN β-1a, subcutaneous, sc, β-1a 22 and 44μg, IFN β-1b, and glatiramer
acetate) [15]. In another study performed in Spain [16], the proportion of adherent patients to
sc IFN β-1b, assessed by the Morisky-Green test, was 68.3%, being indicative of poor adher-
ence. Primary reasons described for non-adherence include adverse reactions (AEs), ‘flu-like
symptoms’, injection anxiety, perceived lack of efficacy, or forgetfulness [15–19]. Among the
strategies aimed at improving the adherence to sc IFN β-1a treatments is the use of autoinjec-
tion devices, such as RebiSmart1 (Merck Serono SA—Geneva, Switzerland), which also
increase significantly the satisfaction of patients [20,21]. In BRIDGE (RebiSmart1 to self-inject
Rebif1 serum-free formulation in a multidose cartridge), a 12-week study involving 119
patients with RRMS, the adherence rate was 88.2% [22]. Despite these encouraging short-term
results, and with the unique exception of a recent published study [23], to date there is no
study evaluating the long-term adherence to sc IFN β-1a treatments in clinical practice. Fur-
thermore, no study has been conducted in Spain with this drug. Therefore, the aim of the pres-
ent study was to determine long-term adherence to sc IFN β-1a treatment administered with
the RebiSmart1 device in patients with RRMS.
Materials and Methods
This retrospective, multicentre, observational nationwide study analysed 258 patients with
RRMS who were receiving sc IFN β-1a treatment (Rebif1) by using RebiSmart1 device. This
study was carried out in 29 hospitals from Spain (Fig 1).
Criteria for study inclusion were as follows: aged 18 or over; diagnosed with RRMS; receiv-
ing sc treatment with IFN β-1a by means of RebiSmart1; using RebiSmart1 device until
replacement (36 months maximum lifetime) or treatment discontinuation, by any cause; elec-
tronic download of adherence data stored in the RebiSmart1 device (using the Mitra1 soft-
ware version 1.5) from start of treatment to replacement/return of the RebiSmart1 device; and
signed informed consent. Exclusion criteria were: having been diagnosed with clinically iso-
lated syndrome, or having primary or secondary progressive MS with no relapses. Patients
were invited to participate in the study at the time of a scheduled visit for device replacement.
The recruitment window for collecting RebiSmart1 devices was 6 months, from June 2013 to
December 2013. Moreover, patients who discontinued the treatment and returned the device
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between October 2009 and August 2013 were also invited to participate in the study. Proce-
dures were performed in accordance with guidelines established by the Ethics Committee of
each participating center, and the Declaration of Helsinki.
Study endpoints
The primary assessment was adherence to the treatment over the retrospective period of obser-
vation, i.e. from the start of sc IFN β-1a treatment to the time of device replacement or treat-
ment discontinuation. Overall adherence was calculated as follows:
100 X
total number of sc IFN b!1a administrations
total number of days
X
7 days
3 administrations
Adherence was quantified by using the data (dosage, time, and date) automatically recorded
by RebiSmart1. The primary endpoint was overall adherence (as continuous outcome)
Fig 1. Geographical location of the hospitals participating in the RELOAD study. This map of Spain shows the localization of the
29 centres (green circles) that participated in the present study. Picture modified from: https://es.wikipedia.org/wiki/Archivo:Espa%C3%
B1aLoc.svg
doi:10.1371/journal.pone.0160313.g001
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supported by the secondary endpoint, percentage of subjects with at least"60%,"70%,"80%,
"90%, and 100% adherence.
Data from adherence were analysed by using the overall period of study and by quarters.
Secondary endpoints included clinical and demographic characteristics of subjects treated with
sc IFN β-1a by using RebiSmart1, the evaluation of disease relapses during the study period,
treatment discontinuation including reasons, and subsequent treatments after discontinuation.
Disease relapse was defined as the reappearance of neurological symptoms during at least 24
hours after a period of time with stable neurological status or after at least 30 days of improve-
ment. Relapses were classified according to the severity (mild, moderate, or sever) of the epi-
sodes. The Expanded Disability Status Scale (EDSS) score was estimated at the time of starting
sc IFN β-1a treatment and when included in the study at the time of device replacement or
treatment discontinuation.
Statistical Analysis
Qualitative variables were expressed as absolute and relative frequencies, and quantitative vari-
ables as the mean with the standard deviation (SD) or the 95% confidence interval (95% CI).
Confidence intervals for rates of adherence were calculated by using Wilson score and Clop-
per-Pearson (Exact) method. A repeated measures analysis of variance (ANOVA) was per-
formed to evaluate differences in overall adherence over time. Statistical significance was
established when p#0.05. A logistic regression model was estimated to identify demographic
and clinical characteristics of patients (including age, sex, geographic location, using a different
IFN β-1a as first DMD treatment, number and severity of relapses, and duration of the treat-
ment) related to achieving an adherence"80%. All statistical analyses were performed by
using SAS software 9.2.
Results
A total of 276 patients were recruited in the study, but only 258 fulfilled all inclusion criteria
and were thus included in the analysis. The study population consisted of mainly women
(67.8% of patients), Caucasian patients (98.8%), with a mean age of 40.7 years and mean body
mass index of 23.9 Kg/m2. Demographic and clinical characteristics of subjects are shown in
Table 1.
Half of patients (51.9%) were employed at the time of inclusion. A total of 34.9% completed
the high school and 29.1% the university. Only 3.9% of patients required a caregiver for assis-
tance. The mean time since diagnosis of RRMS and from onset of symptoms was 8.9 years and
11.3 years respectively. Most of subjects (81.8%) had been using sc IFN β-1a as first DMD treat-
ment. Patients have been receiving Rebif1 with RebiSmart1 device for 3.1 years. Since the
beginning of the IFN β-1a treatment, 106 patients (41.1%) had experienced on average 1.4
relapses (SD: 1.0), with maximum severity being mainly moderate (47.2% of subjects with
relapses) or mild (40.6%). Mean EDSS score was 1.8 (SD: 1.2) at the time of sc IFN β-1a treat-
ment onset and 2.0 (SD: 1.6) at the study inclusion visit (time of device replacement or treat-
ment discontinuation).
Overall adherence during the study period was 92.6% (95% CI: 90.6–94.5%). A total of 78
subjects (30.2%) achieved an adherence rate of 100%, whereas 208 (80.6%) achieved a rate of at
least 90% (Fig 2).
Only 34 subjects (13.2%) showed a suboptimal adherence (<80%) during the study period.
When analysed by quarters (Fig 3), overall adherence at the beginning of the treatment (0–3
months) showed the maximum value (mean: 94.0; 95% CI: 92.0–96.0).
Long-Term Adherence Using RebiSmart1 in RRMS
PLOSONE | DOI:10.1371/journal.pone.0160313 August 15, 2016 4 / 12
From there, overall adherence decreased slightly until 90.4; 95% CI: 87.4–93.3) at the time
of device replacement (n = 150). No significant differences were found between rates of adher-
ence through the study period. The percentage of subjects with suboptimal adherence by 3
months periods was about 10% throughout the study period (range: 8.1–13.2%).
According to the logistic regression model, having experienced relapses from the beginning
of the sc IFN β-1a treatment was the only variable associated with achieving an adherence of at
least 80% (OR: 3.06, 95% CI: 1.28–7.31). The incidence of relapses decreased over time, from
15 cases at the beginning of the treatment (5.8%, n = 258 at 0–3 months) to 6 cases at the time
of device replacement (4.0%, n = 150 at 33–36 months; Fig 4). Relapses were mainly mild or
moderate in severity.
A total of 89 patients (34.5%) discontinued the treatment before device replacement mainly
due to the following reasons: occurrence of AEs (12.8% of patients), perceived lack of efficacy
Table 1. Demographic and clinical characteristics of patients.
Total(N = 258)
Sex, female, n (%) 175 (67.8)
Race, Caucasian, n (%) 255 (98.8)
Age, mean years (SD) 40.7 (9.5)
BMI, mean Kg/m2 (SD) 23.9 (3.8)
Employment status, n (%)
Employed 134 (51.9)
Unemployed 33 (12.8)
Retired 24 (9.3)
Unpaid housework 14 (5.4)
Student 7 (2.7)
Not available 46 (17.8)
Educational level, n (%)
Primary 41 (15.9)
High school 90 (34.9)
University 75 (29.1)
No studies 1 (0.4)
Not available 51 (19.8)
Requiring a caregiver, n (%) 10 (3.9)
Time since diagnosis of RRMS, mean years (SD) 8.9 (6.0)
Time since onset of symptoms, mean years (SD) 11.3 (6.9)
Patients using sc IFN β-1a as first DMD treatment, n (%) 211 (81.8)
Time since the start of the treatment, mean years (SD) 3.1 (0.8)
Patients with relapses since the beginning of the treatment, n (%) 106 (41.1)
Number of relapses, mean (95% CI) 1.4 (1.2–1.6)
Maximum severity of relapse: Mild, n (%) 43 (40.6)
Moderate, n (%) 50 (47.2)
Severe, n (%) 6 (5.7)
Not available, n (%) 7 (6.6)
EDSS score, mean (SD)
At start of sc IFN β-1a treatment (baseline) 1.8 (1.2)
At inclusion in the study (last time point) 2.0 (1.6)
SD, standard deviation; BMI, body mass index; RRMS, relapsing-remitting multiple sclerosis; sc,
subcutaneous; DMD, disease modifying drug; EDSS, Expanded Disability Status Scale
doi:10.1371/journal.pone.0160313.t001
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(10.8%), voluntary decision (8.1%), and non-adherence to the treatment (6.2%). Discontinua-
tion of the treatment, reasons, and subsequent treatments are shown in Table 2.
The occurrence of AEs was 15 cases during the first year (5.8%, N = 258), 13 during the sec-
ond (5.6%, N = 233), and 5 during the third (2.5%, N = 203). Discontinuation remained at a
constant rate through the study period, with a mean value of 3.4% of subjects (95% CI: 2.7–
4.1%) each quarter. Finally, main treatments after discontinuation were: glatiramer acetate
(22.5% of the changes, 20/89), fingolimod (13.5%, 12/89), natalizumab (12.4%, 11/89), and
IFN β-1a intramuscularly (9.0%, 8/89).
Discussion
Despite the demonstrated clinical effectiveness of DMDs by reducing the incidence and sever-
ity of relapses and disability progression in RRMS [4–7,24], adherence to injectable DMD ther-
apies is generally suboptimal [10], which compromises their potential beneficial effects. Data
from the GAP project revealed an overall non-adherence rate of 25% to intramuscular IFN β-
1a, sc IFN β-1a, IFN β-1b, and glatiramer acetate first-line DMD treatments [15]. Moreover,
adherent patients showed a significant better quality of life, fewer neuropsychological issues,
shorter duration of disease, and shorter duration of therapy than non-adherent patients. These
results highlighted the importance of adherence on the effectiveness of the DMD treatments
Fig 2. Adherence to the treatment. Percentage of patients achieving ("60%,"70%,"80%,"90%, or 100% adherence to sc IFN β-1a treatment over 36
months of the study period (N = 258). The number of patients and the respective percentage is depicted above each bar.
doi:10.1371/journal.pone.0160313.g002
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and the need of identify the causes that lead to non-adherence. The most common reported
reasons for non-adherence included forgetting to administer the injection, followed by tired-
ness of taking injections, fatigue, ‘flu-like symptoms’, and pain.
Maintaining the adherence to injectable treatments may be a challenge for some patients
when managing a chronic disease. Electronic injection devices, such as RebiSmart1, have been
developed with the purpose to overcome specific problems associated with the injection (nee-
dle phobias, anxiety, or pain at the injection site) [21,25,26]. When comparing with manual
injections, autoinjectors have demonstrated to improve the injection tolerability and thus the
satisfaction of the subject [27–30]. For this reason, the advance of these electronic injection
devices has led to the improvement of adherence to sc IFN β-1a treatment, as demonstrated in
the 12-week BRIDGE study, with a rate of adherence of 88.2% [22]. Subjects reacted favourably
to those features of the device associated with handling, while being easy to use. Similarly, it
has been recently published a study of adherence over 24 months in 225 patients with RRMS
from the United Kingdom (UK) and Ireland who were receiving sc IFN β-1a treatment by
RebiSmart1 [23]. In this population, the rate of overall adherence was 95.0%, showing 92.0%
of subjects with an adherence"80% at 12 months and 91.1% at 24 months. In our study, the
overall rate over the course of 36 months (92.6%) was in concordance with previous studies
using the same RebiSmart1 device, corroborating its beneficial effect on improving the adher-
ence to the treatment. In our study, the only demographic and clinical variable from subjects
Fig 3. Adherence to the treatment by quarters.Overall adherence to sc IFN β-1a treatment over 36 months of the study period and
analysed by quarters. The mean value of the overall adherence in each quarter is depicted above the respective bar. The total number
(N) of patients included in each quarter is shown below the graphic.
doi:10.1371/journal.pone.0160313.g003
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related with an adherence of at least 80% was having (or not) experienced relapses from the
beginning of the sc IFN β-1a treatment. Indeed, suboptimal adherence was about 3 times
higher in subjects who had suffered relapses than in those who had not. Furthermore, 58.9% of
the subjects did not experience any relapse since the beginning of the treatment, thus corrobo-
rating its effectiveness in reducing the incidence of relapses [4–8]. A total of 34.5% of subjects
discontinued the treatment before device replacement because of the occurrence of adverse
events, perceived lack of efficacy, voluntary decision, or non-adherence. In our study, discon-
tinuation remained at a constant rate through the study period, in contrast to what has been
reported in the literature, occurring more likely in the first 6 months of treatment [10]. Those
subjects who discontinued the treatment, mainly switched to glatiramer acetate, or to the sec-
ond-line agents fingolimod or natalizumab. RebiSmart1 device also can record the dose his-
tory, allowing the capture of accurate and objective information, useful to detect suboptimal
Fig 4. Relapses occurred during the treatment. Incidence (upper graph) and severity (lower graph) of relapses over 36 months of the
study period and analysed by quarters. The incidence of relapses is analysed by determining the mean number of relapses in each
quarter of time. The severity of relapses in each quarter of time is classified in mild (light grey portion of the bar), moderate (dark grey), or
severe (black). The percentage of mild, moderate and severe relapses experienced in each quarter is shown below the graphic.
doi:10.1371/journal.pone.0160313.g004
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adherence in patients and to avoid potential lack of efficacy. This feature becomes especially
important for patients with memory or attention impairment. The present study has several
strengths. It evaluated the effect of using an electronic device which may inform about the
adherence to disease-modifying therapies. This fact allows avoiding healthcare database as a
source of information. Therefore, this device is able to monitor adherence objectively in con-
trast to database studies, using medication possession ratio. The main limitation of the study
was its retrospective nature. Furthermore, there is the possibility of a selection bias derived
from the fact that patients aware of their non-adherence may tend to not participate voluntarily
in the study. However, and unfortunately, this potential bias is intrinsically present in all stud-
ies in this field. Another issue, is the fact that although the patients were selected by the time of
device replacement or treatment discontinuation, the age range was relatively small, and there-
fore we must accept the possibility that a hidden age selection bias could have been inadver-
tently occurred, when prescribing the RebiSmart1 device, as younger patients are more prone
to use efficiently new technologies.
In conclusion, results of this study indicate that sc IFN β-1a administration facilitated by
RebiSmart1 in patients that accepted it, could lead to high rates of adherence to a prescribed
dose regimen over 36 months. This adherence was above 90% on average over the three years
of use. Advances in electronic injection devices such as RebiSmart1 permit adherence to be
recorded and monitored by the device itself, thereby improving comfort, subject satisfaction,
and the adherence to the treatment of patients in this chronic disease.
Table 2. Discontinuation of the treatment, reasons, and subsequent treatments.
Total
Total number of patients that discontinued, n/total N (%) 89/258 (34.5)
0–3 months 5/258 (1.9)
3–6 months 10/253 (4.0)
6–9 months 7/243 (2.9)
9–12 months 10/236 (4.2)
12–15 months 11/226 (4.9)
15–18 months 10/215 (4.7)
18–21 months 8/205 (3.9)
21–24 months 7/197 (3.6)
24–27 months 5/190 (2.6)
27–30 months 6/185 (3.2)
30–33 months 2/179 (1.1)
33–36 months 8/177 (4.5)
Rate of discontinuation each quarter, mean (95% CI) 3.4 (2.7–4.1)
Main reasons for discontinuation, n/total N (%)
Occurrence of adverse events 33/258 (12.8)
Perceived lack of efficacy 28/258 (10.8)
Voluntary decision 21/258 (8.1)
Non-adherence 16/258 (6.2)
Main subsequent treatments after discontinuation, n /N discontinued (%)
Glatiramer acetate 20/89 (22.5)
Fingolimod 12/89 (13.5)
Natalizumab 11/89 (12.4)
IFN β-1a intramuscular 8/89 (9.0)
95% CI, 95% confidence interval
doi:10.1371/journal.pone.0160313.t002
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